Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94

Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94

We evaluated long-term outcome and genomic profiles in the Austrian Neuroblastoma Trial A-NB94 which applied a risk-adapted strategy of treatment (RAST) using stage, age and <i>MYCN</i> amplification (MNA) status for stratification. RAST ranged from surgery only to intensity-adjusted che...

Full description

Bibliographic Details
Main Authors: Stefan Fiedler, Inge M. Ambros, Evgenia Glogova, Martin Benesch, Christian Urban, Marlene Mayer, Georg Ebetsberger-Dachs, Edit Bardi, Neil Jones, Agnes Gamper, Bernhard Meister, Roman Crazzolara, Gabriele Amann, Karin Dieckmann, Ernst Horcher, Reinhold Kerbl, Bettina Brunner-Herglotz, Andrea Ziegler, Peter F. Ambros, Ruth Ladenstein
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
neuroblastoma
Austrian trial A-NB94
biomarkers
Online Access:https://www.mdpi.com/2072-6694/13/3/572

Internet

https://www.mdpi.com/2072-6694/13/3/572

Similar Items